Gen Z Ditches Diet and Exercise: Surging Demand for GLP-1 Weight-Loss Drugs Among India’s Youth Sparks Expert Warnings

Gen Z is increasingly turning to powerful weight-loss drugs as a fast fix rather than adopting a “wait and watch” approach, with doctors in India reporting rising demand from young adults in their early 20s who may not even meet medical criteria for these medications. At the same time, global data show a steep surge in the use of GLP-1 (glucagon-like peptide-1)–based drugs like semaglutide among adolescents and young adults, raising urgent questions about safety, cost, body-image pressures, and how best to manage weight in a generation living online.​

Gen Z’s new weight-loss playbook

A recent report in ET Healthworld describes how young Indians in their late teens and 20s are asking for blockbuster GLP-1–based weight-loss drugs, sometimes for “cosmetic” reasons such as looking slimmer on social media or on screen, rather than for medical obesity. One Mumbai endocrinologist cited in the report described turning away a woman in her early 20s who requested a GLP-1 after her body mass index (BMI) rose from 21 to 22—well within the healthy range—because there was no medical indication for such treatment.​

Clinicians quoted in the article say that while some Gen Z patients have genuine reasons—obesity with conditions like polycystic ovary syndrome (PCOS), early diabetes, sleep apnoea or fatty liver—a “significant number” are seeking drugs mainly to drop a few kilos rapidly. Another physician stressed that most young people in this cohort can lose weight effectively with structured diet and exercise, and “ideally do not require these drugs.”​

What are GLP-1 drugs and when are they indicated?

GLP-1 receptor agonists such as semaglutide and related drugs were first approved for type 2 diabetes in 2005 and later for chronic weight management in people with obesity or overweight plus a weight-related condition. These medicines act on hormones that regulate appetite and blood sugar, helping people feel fuller, eat less, and lose significant weight over time when used alongside lifestyle changes.​

Current approvals in major markets, including the United States, restrict higher-dose semaglutide for weight management (for example, Wegovy) to individuals with a BMI of at least 30, or 27 with conditions like hypertension, diabetes or dyslipidaemia, not to people with normal BMI seeking cosmetic slimming. Clinical guidelines generally position GLP-1 drugs as second-line options after supervised lifestyle interventions and, in some cases, other therapies, because they are expensive, require long-term use, and still lack decades of safety data in youth.​

A global surge among young users

Evidence from a national US study of pharmacy data shows how fast use of these drugs is rising among adolescents and young adults aged 12–25. Between 2020 and 2023, monthly dispensing of GLP-1 receptor agonists in this age group increased by 594 percent, with the steepest rise in females.​

The study reported that:

• Use in female adolescents (12–17 years) increased by 588 percent, compared with 504 percent in males.​

• Use in female young adults (18–25 years) rose by 659 percent, versus 481 percent in male peers.​

Researchers also observed substantial dispensing of Ozempic (semaglutide for diabetes) in youth despite it not being approved for weight management in adolescents, suggesting significant off-label use. The authors called for closer monitoring of safety, especially around growth, development and pregnancy in young female users, and highlighted that the drugs are costly and designed for long-term use.

Why Gen Z is skipping “wait and watch”

Experts and market analysts point to several forces behind the “no weight & watch” mindset among Gen Z:

• Social media aesthetics and pressure: Doctors in India report that young patients explicitly mention wanting to “look thinner” for social media content or on-screen appearances, linking drug use to curated online identities rather than health outcomes.​

• Instant-result culture: GLP-1s promise double-digit percentage weight loss in trials over months, which can feel more attractive than slow, hard-won progress through diet and physical activity, especially for a generation accustomed to rapid digital feedback.​

• Tech-enabled wellness: Coverage of the “consumer-driven future” of GLP-1s highlights how pills, influencer-led content, and weight-loss apps are reshaping the obesity market into a demand-led ecosystem where patients often arrive at the clinic already asking for a specific brand.​

At the same time, survey data suggest many Gen Z consumers struggle to maintain motivation for regular exercise, with around 44 percent reporting difficulty staying active, higher than older adults. This mix of online pressure, convenience, and adherence challenges creates a powerful pull towards pharmaceutical shortcuts.​

Obesity burden and real medical need

India’s rising metabolic risk burden provides an important backdrop. A large national study from the Indian Council of Medical Research (ICMR-INDIAB) described an “alarming” burden of obesity and related risk factors, estimating around 254 million adults with generalised obesity and 351 million with abdominal obesity. The study classified people into metabolic health and obesity subtypes and found that those with both obesity and metabolic abnormalities had markedly higher odds of type 2 diabetes and coronary artery disease compared with metabolically healthy, normal-weight adults.​

Other recent analyses of adolescents in India report overweight prevalence ranging from about 5.8 percent to nearly 35 percent, and obesity from 0.3 percent to over 18 percent, reflecting wide variability but underscoring that youth overweight and obesity are genuine public health concerns. These data support the need for effective tools—including medication—when used appropriately in young people with clear medical risk.Expert concerns: safety, overuse and off-label prescribing

Endocrinologists and primary-care physicians quoted in the Indian report warn that the pendulum may be swinging too far towards aggressive drug use among otherwise healthy young adults. One consultant described seeing a “sharp rise” in Gen Z demand for weight-loss injections, noting that many requests come without adequate attempts at diet and exercise or any serious metabolic disease.

International experts echo these worries. The lead author of the JAMA study on GLP-1 use in youth emphasised that the dramatic rise in prescribing makes it critical to understand long-term safety, efficacy, and cost-effectiveness in adolescents and young adults. Another senior author highlighted the need to educate young women about potential pregnancy-related safety concerns and flagged the scale of off-label Ozempic use in teens and young adults as a red flag.​

Social media, hype and mixed attitudes

Beyond clinical settings, social media is shaping how young people think about GLP-1 drugs. Content analyses of Reddit and other platforms show a large volume of user posts about semaglutide, Mounjaro and related agents, with discussions spanning weight loss, side effects and even untested potential benefits such as reduced cravings for alcohol.​

Not all Gen Z users are enthusiastic. Separate reporting on US youth attitudes has found substantial skepticism about GLP-1 drugs among younger Americans, who worry about hype, safety risks and over-medicalisation of body weight, and often say they prefer “natural” approaches like diet and exercise when possible. This tension between curiosity, concern and caution mirrors broader debates in obesity care.​

What this means for everyday health decisions

For health-conscious readers—especially young adults—the key practical messages from experts are:

• These are medical treatments, not quick-fix beauty tools: Guidelines and regulators intend GLP-1 drugs for people with obesity or overweight plus health risks, not for normal-weight individuals aiming for a sharper jawline or a certain “Insta-ready” look.​

• Lifestyle still matters: Clinicians stress that structured nutrition, physical activity, sleep and mental health support remain first-line tools, particularly for relatively young, otherwise healthy people who may respond well without medication.​

• Ask about risks, benefits and costs: GLP-1s can cause side effects like nausea, vomiting and gastrointestinal upset, and long-term safety in adolescents and young adults is still being studied, while the high cost and need for ongoing use can pose financial and emotional burdens.​

• Beware of off-label and online offers: Experts caution against sourcing these drugs through unregulated online vendors, wellness influencers, or without proper medical assessment, as quality, dosing and follow-up may be unsafe.​

For clinicians, the emerging trend underscores the need to screen for body-image distress, social-media-driven expectations, and mental health concerns when young patients request weight-loss drugs, and to ensure that prescriptions follow evidence-based indications and shared decision-making.

Limitations and unanswered questions

Much of the available hard data on GLP-1 use in youth comes from high-income countries and pharmacy databases, which may not fully capture access patterns, informal prescribing or non-prescription use in countries like India. The Indian reportage currently relies largely on clinician observations and patient anecdotes, which, while valuable, need to be complemented by systematic national data on prescribing, adherence and outcomes in Gen Z populations.​

Long-term effects of taking GLP-1 drugs from adolescence or early adulthood—including impacts on growth, reproduction, mental health, and weight trajectory after stopping treatment—are still under study, and experts repeatedly call for longer follow-up and more diverse trial populations. There is also limited understanding of how social media, influencer culture and digital weight-loss tools interact with clinical care to shape behaviour in Gen Z, making this a priority area for future public health and behavioural research.​

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

News and commentary

• ET Healthworld. “No weight & watch approach in Gen Z’s main weightloss plan.” The Economic Times Healthworld. Published December 30, 2025.economictimes.indiatimes​